Key Highlights
- Craneware plc (LSE:CRW) traded around 1,100p on 15 and 16 October 2026, a modest recovery from the September low but far below levels seen earlier in the year.
- The US hospital software group reset revenue expectations for the current year to about 185 million dollars after 340B disruption and a cyber incident.
- Directors have been active, with a non-executive buying shares and the chief executive keeping his full share award.
- The final dividend of 17p goes ex on 3 December, while the board pursues a cost review and targets a return to growth in the 2028 financial year.
Why Craneware plc (LSE:CRW) Is in Focus Today
Craneware plc (LSE:CRW), the Edinburgh-based provider of financial and operational software to US hospitals, remains one of the most closely watched recovery situations in the FTSE AIM 100. On 15 October, the shares closed around 1,104p, up slightly on the day, before easing by close to 1 percent on 16 October to roughly 1,094p. That leaves the stock some way above its post-results low near 996p, but still around half its value at the start of 2026.
The only formal update on 15 October was a routine block admission return confirming no new shares were issued under employee schemes. The real debate is whether September's heavy fall has already priced in the bad news.
Latest Developments
On 21 September, Craneware plc (LSE:CRW) published results for the year to 30 June 2026. Revenue was broadly flat at about 206 million dollars, and annual recurring revenue edged up to around 185 million dollars. Adjusted EBITDA rose about 3 percent to a little over 67 million dollars, giving a margin of roughly a third, and statutory profit before tax improved. The total dividend was held at 32p.
The shock came in the outlook. The board reset revenue expectations for the current year to roughly the level of annual recurring revenue, about 185 million dollars, implying a meaningful decline. Net revenue retention fell to 100 percent from more than 107 percent. The shares fell by around a quarter on the day.
Two issues drove the reset. First, disruption to the US 340B drug pricing programme delayed customer decisions on Craneware's pharmacy-related products. Second, a cyber security incident disclosed in July, which affected a significant volume of customer and partner records, remains under investigation and its financial impact has not yet been quantified. The company said core operations and customer services were not disrupted.
Business and Financial Backdrop
Craneware's Trisus platform helps US hospitals manage pricing, revenue integrity, pharmacy spend and operational productivity. The company has invested heavily in artificial intelligence, with its Trisus Assist layer now used by more than 400 customers and new tools such as Reimbursement Intelligence turning payer contracts into pricing rules. A 340B-focused product, Trisus OneLink Medication, has been launched to support new reimbursement models.
Financially, the group remains profitable and cash generative, with cash conversion close to 100 percent. Bank debt increased after a revolving credit facility drawdown that helped fund a 25 million dollar share buyback in the spring. The board has started a cost review and expects to maintain its margin in the medium term.
Sector and Market Context
The 340B programme allows qualifying US hospitals to buy outpatient drugs at discounted prices, and it is a major source of income for many of Craneware's customers. In recent years, drug manufacturers have pushed for a rebate model rather than upfront discounts. A federal court ruling in July found that rebate models are permitted with government approval, and the health regulator has announced a revised rebate pilot due to start on 1 January 2027. The uncertainty has caused hospitals to delay purchasing decisions, but greater clarity could ultimately increase demand for software that tracks claims and rebates.
Management has said it expects conditions to become more supportive during the current year, particularly in the second half, though these potential tailwinds are not included in guidance.
Analyst and Investor Sentiment
Analysts remain broadly positive in their ratings, though targets have been cut. Market commentary after the results said the 340B disruption proved more severe than previously expected, while some brokers argued that the programme is too important to hospitals to be abandoned and should eventually support growth.
Directors have shown some confidence. Non-executive director Susan Nelson bought shares at around 1,054p in late September, and chief executive Keith Neilson, who holds close to a tenth of the company, chose to keep his entire vested share award rather than selling to cover tax. Social media chatter remains divided between value seekers and those wary of further downgrades.
What Investors Are Watching Next
Key items include the annual general meeting, typically held in the autumn, where the board may comment on trading; the final dividend, which goes ex on 3 December and is payable on 22 December; and updates on the cyber investigation. Interim results, usually published in the early part of the calendar year, will show whether the revenue reset is proving conservative. Progress on the cost review and the 340B rebate pilot from January will be central for Craneware plc (LSE:CRW).
Key Risks
Risks include further delays in US hospital spending, regulatory or legal setbacks around 340B, unquantified costs or reputational damage from the cyber incident, customer churn, and currency swings between the dollar and sterling.## Frequently Asked Questions
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...